Canada is Failing Millions Living With Arthritis – But a Bold Plan Aims to End the Disease
The State of Arthritis in Canada Report Card Arthritis Society Canada Arthritis Action Now unites 21 organizations, more than 100,000 patients,...
Disability
Arthritis Foundation Invites the Public to Join Green Heart Fridays During Arthritis Awareness Month
Nationwide Free Art Activation Returns for Arthritis Awareness Month ATLANTA, GA / ACCESS Newswire / April 7, 2026 / This...
Arthritis Foundation Invites the Public to Join Green Heart Fridays During Arthritis Awareness Month
Nationwide Free Art Activation Returns for Arthritis Awareness Month ATLANTA, GA / ACCESS Newswire / April 7, 2026 / This...
Enlyte Completes Acquisition of PartsTrader
Investment strengthens PartsTrader's open procurement platform across the collision repair ecosystemSAN DIEGO, April 6, 2026 /PRNewswire/ -- Enlyte, a leader in...
Todd H. Lanman to Present First Full U.S. IDE Trial Results for FDA-Approved Synergy Disc(R) at ISASS 2026
Beverly Hills spine surgeon and principal investigator will present pooled clinical outcomes following recent FDA approval of motion-preserving cervical disc...
Leverage Cognitive Data to Improve Sleep-Wakefulness Drug Evaluation, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn the importance of measuring cognition in sleep medicine trials. The featured speaker will share considerations...
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
Axsome obtains exclusive global rights to balipodect, a potentially first-in-class selective phosphodiesterase 10A inhibitor Acquisition further expands Axsome’s industry-leading CNS...
Sun Life U.S. announces continued support of the Gap Year Program at Northeastern University’s Roux Institute in honor of recently retired company president, Dan Fishbein, M.D.
The Roux Institute runs a program that helps expand access to care throughout MainePORTLAND, Maine, March 31, 2026 /PRNewswire/ --...
Guardian completes integration with FINEOS to expand digital capabilities and deliver a simplified leave experience
New absence capabilities strengthen the company's ability to deliver a modern and connected leave experience for employees and the HR...
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy
Program to be externally funded by a venture philanthropy agreement through clinical proof-of-concept, including the Phase 1/2 study planned to...
BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease
Data showed 50% or more of patients reporting >50% improvement in key pain and function scales No adverse events related...
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing...
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460...
Valid8 Financial: Upstate New York District Attorney Secures Convictions in Complex Investigations Involving $300K in Losses
Valid8 Financial's forensic accounting software accelerated prosecutions in elder exploitation and child neglect cases.NEW YORK, March 24, 2026 /PRNewswire/ --...
RethinkCare Unveils Major Enhancements to Support Neurodivergent and Disabled Communities
Enhanced offering delivers coordinated human-plus-digital support that addresses long-standing gaps in workplace benefits for neurodivergent and disabled communitiesNEW YORK, March...
Persica Pharmaceutical’s PP353 Phase 1b Data Selected for Oral Presentation at the American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting
ASIPP presentation follows publication of positive data from PP353 Phase 1b Modic Trial in The Lancet’s eClinicalMedicine London, UK, 19 March...
RethinkCare Delivers 119% ROI for Employers, Forrester Study Finds
Independent Total Economic Impact™ study shows $2 million net present value (NPV) and payback in under six monthsNEW YORK, March...
EMR Syndrome Alliance Launches Website for People Injured or Disabled by Man-Made Electromagnetic Radiation (EMR)
Education, remediation, disability and recovery resources are now available for those suffering acute effects from radiation emitted by cell towers and...
Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren’s Syndrome
DUBLIN and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused...
George Medicines extends global commercialization of GMRx2 into Australia and New Zealand with Arrotex licensing agreement
Arrotex gains exclusive rights in Australia and New Zealand to innovative single pill combination of three hypertension medicines, including two...